

ASX Announcement

2 July 2026

BCAL acquires shares in Genetic Signatures

Highlights

- **BCAL to acquire 23,173,644 shares (10.2%) in Genetic Signatures Ltd for cash of \$1,390,119, or 6.0 cents per share.**
- **BCAL's current product portfolio in early cancer detection is synergistic with Genetic Signatures infectious disease diagnostics capability.**
- **Potential to leverage complementary capabilities (products, pipeline, partnerships) to support future growth opportunities.**
- **Genetic Signatures has potential to provide BCAL with exposure to broader diagnostics infrastructure, regulatory capability and international markets in Asia Pacific, EMEA and the US.**

BCAL Diagnostics Limited (ASX: BDX), an Australian healthcare company pioneering diagnostics for early detection of cancer, is acquiring 10.2% of Genetic Signatures Ltd (ASX: GSS), a complementary molecular diagnostics company. Both companies have product in market and are revenue generating.

Under the transaction, BCAL will acquire 23,173,644 Genetic Signatures shares for cash of \$1,390,119, at 6.0 cents per share.

Genetic Signatures is a specialist molecular diagnostics company focused on commercialising its proprietary platform technology. The company has released a suite of real-time PCR-based products for the routine detection of infectious diseases under the EasyScreen™ brand.

BCAL believes the strategic rationale for this complementary share acquisition is the potential to gain access to Genetic Signatures' platform, its established commercial operations, active paying customers in Australia, the UK and the US, and international market access channels across Asia Pacific, EMEA and the US.

The investment provides BCAL with an opportunity to add an additional diagnostics pillar to BCAL's existing focus on early cancer detection. BCAL believes Genetic Signatures' infectious disease PCR platform is complementary to BCAL's oncology liquid biopsy and breast cancer diagnostics portfolio.

Genetic Signatures has achieved FDA 510(k) clearance for its EasyScreen™ Gastrointestinal Parasite Detection Kit and GS1 automated workflow, representing a key regulatory milestone for US IVD market access. The company also has validated PCR manufacturing capability for CE-IVD and FDA-cleared products, providing regulatory and compliance infrastructure that BCAL considers valuable.

BCAL also sees potential for Genetic Signatures' laboratory, manufacturing, distribution and technical support infrastructure to support broader commercialisation opportunities over time.

BCAL CEO Anne-Louise Arnett said: *"This is a great way for BCAL to establish a strategic position in a complementary diagnostics company with existing infrastructure, international market access channels and the potential to support broader growth opportunities over time, complementing our oncology diagnostics portfolio, including Avantect® and BREASTESTplus™ 2.0.*

BCAL Chair Jayne Shaw said: *"Genetic Signatures gives BCAL exposure to an additional diagnostics pillar in infectious disease, while supporting our broader strategy to build a stronger diagnostics platform across cancer and molecular testing. We see many ways to work together for the benefit of both companies."*

This announcement has been approved for release by the Board of BCAL.

ENDS

For further information:

Anne-Louise Arnett

Chief Executive Officer

aarnett@bcaldiagnostics.com

About BCAL Diagnostics

BCAL is an Australian health care company engaged in early cancer detection. BCAL launched its first test BREASTEST^{plus}™ as a 'rule-out' test designed to be used in the clinical evaluation of breast disease for women with dense breasts. BREASTEST^{plus}™ is a simple, non-invasive blood test used in conjunction with mammography to improve screening and diagnostic outcomes for breast health in women.

BCAL holds exclusive license with ClearNote Health Inc., a US-based precision diagnostics company, for the sale and distribution of Avantect Pancreatic, Avantect Ovarian and Avantect multi-cancer blood tests in Australia and New Zealand.

BCAL is headquartered in Sydney, Australia and listed on the Australian Securities Exchange (ASX: BDX). For more information: <https://www.bcaldiagnostics.com/> or contact info@bcaldiagnostics.com.

About Genetic Signature Ltd

Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3base®.

Genetic Signatures has released a suite of real-time PCR based products for the routine detection of infectious diseases under the EasyScreen™ brand. This proprietary MDx technology provides hospitals and pathology laboratories with the ability to screen for a wide array of infectious pathogens.